{
    "clinical_study": {
        "@rank": "26865", 
        "arm_group": [
            {
                "arm_group_label": "ELS-M11", 
                "arm_group_type": "Experimental", 
                "description": "Topical 5% ELS-M11 (3 g)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A matching formulation with no active ingredient"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase Ib, 12-week, multi-center, randomized, double-blind, cross-over,\n      placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo\n      in 50 male and female subjects, aged 18 to 65 years that suffer recurring moderate-severe\n      migraine headaches (2-8 per month).\n\n      This study is designed to describe the efficacy and safety of ELS-M11 as compared to\n      placebo."
        }, 
        "brief_title": "Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Headaches", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Achelios is developing ELS-M11 for topical application for the acute treatment of migraine\n      events in patients with a history of migraine with or without aura.\n\n      To be eligible for the study, patients must have a one-year documented history of migraine\n      headache (as defined by the International Headache Society IHS), with or without aura, with\n      2\u22648 moderate or severe migraine attacks per month in the 2 months prior to the screening\n      visit.\n\n      The total duration of the study is the completion of five migraine headaches per subject\n      over a maximum 12 week period followed by a 3-14 day Follow-Up Period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent\n\n          -  Males and females aged 18-65 who can read, write and understand English\n\n          -  Subject has at least a one year documented history of migraine headache (defined by\n             International headache Society IHS) migraine definitions, with or without aura, with\n             2\u22648 moderate or severe migraine attacks per month in the 2 months prior to the\n             screening visit\n\n          -  Is stable on the current standard non-opioid rescue medication for at least 2 months\n             prior to randomization\n\n          -  Can distinguish migraine from tension headache (HA), with 24 hours of freedom from HA\n             between migraine events\n\n          -  Women of childbearing potential must be currently using or willing to use\n             contraception (30 days prior to start of study medication and for 21 days after\n             taking study medication)\n\n          -  Women of non-childbearing potential include females regardless of age, with\n             functioning ovaries and who have a current documented tubal ligation [Hatcher, 2004]\n             bilateral oophorectomy or total hysterectomy, or post-menopausal females\n\n          -  The subject is able and willing to perform the assessments and procedures as\n             specified in this protocol, including the ability to learn and follow instructions\n             for ePRO device\n\n        Exclusion Criteria:\n\n          -  Migraineurs taking opioid-based rescue medications for any indication\n\n          -  Subject has history of mild migraine events or migraines that usually resolve\n             spontaneously in less than 2 hours\n\n          -  Subject has menstrual migraines\n\n          -  Positive Drug Test\n\n          -  Subject has basilar or hemiplegic migraines\n\n          -  Subject has more than 15 headache-days per month\n\n          -  Subjects with a history of facial allodynia\n\n          -  Subject has a history of vomiting during more than 30% of migraine episodes\n\n          -  Self confinement to bed rest for more than 50% of migraine episodes\n\n          -  Subject was greater than 50 years old at age of migraine onset\n\n          -  Acute coronary syndrome (i.e., myocardial infarction and unstable angina), stroke or\n             resuscitated cardiac arrest within the past 3 months\n\n          -  Severe congestive heart failure\n\n          -  Systolic blood pressure (sBP) >160 mmHg or diastolic blood pressure (dBP) >100 mmHg\n             measured in the sitting position at Visit 1\n\n          -  Current active renal disease\n\n          -  Any history of pyelonephritis\n\n          -  Evidence of active liver disease\n\n          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline\n             phosphatase >2 times the upper limit of the reference range (ULRR), or total\n             bilirubin >1.5 times the ULRR at Visit 1\n\n          -  Past history of acute pancreatitis with current triglycerides 4.56 mmol/L (400 mg/dL)\n             at Visit 1\n\n          -  History of malignancy within the past 3 years, other than non-melanoma skin cancer\n             (i.e., basal or superficial squamous cell carcinoma) and treated cervical cancer\n             in-situ\n\n          -  Any planned major surgery to be performed during the study (e.g., coronary artery\n             bypass surgery, abdominal aortic aneurysm repair, etc.)\n\n          -  Current life-threatening condition\n\n          -  Significant hypersensitivity to NSAIDs (e.g., difficulty swallowing or breathing,\n             tachycardia, anaphylaxis, angioedema or skin reaction)\n\n          -  Pregnancy (defined by positive urine pregnancy test) or lactation at Visit 1, or\n             planning to become pregnant prior to completion of the study\n\n          -  History or suspicion of alcohol or substance abuse (current or past 6 months).\n\n          -  Participation in any clinical trial within 30 days prior to Visit 1\n\n          -  Subjects with a history of hypersensitivity to products containing tiaprofenic acid,\n             suprofen, fenofibrate, oxybenzone, or octocrylene (e.g., sunscreen, perfume)\n\n          -  Subjects with a history of photosensitivity\n\n          -  Any clinically significant abnormality or any reason that the subject may not be able\n             to complete the full study observational period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057315", 
            "org_study_id": "ACH10200"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ELS-M11", 
                    "Placebo"
                ], 
                "description": "One dose of 5% ELS-M11 over 3 bilateral applications.", 
                "intervention_name": "ELS-M11", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ELS-M11", 
                    "Placebo"
                ], 
                "description": "One dose of matching placebo over 3 bilateral applications.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Migraine headache", 
            "Photophobia", 
            "Phonophobia", 
            "Aura", 
            "Topical treatment"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48104"
                    }, 
                    "name": "Michigan Head Pain and Neurological Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Coastal Carolina Research Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Cross-Over, Placebo-Controlled Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine", 
        "overall_contact": {
            "email": "james.kelly@wwctrials.com", 
            "last_name": "James Kelly"
        }, 
        "overall_official": {
            "affiliation": "Achelios Therapeutics, Inc.", 
            "last_name": "Crist J. Frangakis, Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pain relief (as defined by a one point decrease on a 4 point pain intensity scale) in subjects experiencing a moderate to severe migraine headache, 2 hours after the initial application of ELS-M11.", 
            "measure": "Percentage of patients who experience pain relief 2 hours following the first application of ELS-M11", 
            "safety_issue": "No", 
            "time_frame": "2  hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain relief (as defined by a one point decrease on a 0-3 point pain intensity scale) in subjects experiencing a moderate to severe migraine headache over a 24 hour period following the first application of ELS-M11.", 
                "measure": "Percentage of patients who report pain relief at various time points within a 24 hour period, following the first application of ELS-M11", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Complete resolution (intensity score of 0 on a 0-3 pain scale) of migraine pain within 24 hours, following ELS-M11 application in subjects experiencing a moderate to severe migraine headache.", 
                "measure": "Percentage of patients who report complete pain resolution within 24 hours following the first application of ELS-M11.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Sustained pain relief defined as pain relief by 2 hours post study medication application with no increase in the pain intensity score up to 24 hours post medication application in moderate and severe headaches, following ELS-M11 application.", 
                "measure": "Percentage of patients who report sustained pain relief after the first application of ELS-M11", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Sustained complete pain resolution defined as pain free by 2 hours post study medication application with no change in a pain intensity score of 0 up to 24 hours post medication application in moderate and severe headaches, following ELS-M11 application.", 
                "measure": "Percentage of patients who report sustained complete pain resolution after the first application of ELS-M11.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Time to Initial Use of Rescue Medication following ELS-M11 application in subjects experiencing moderate to severe headaches within a 24 hour period", 
                "measure": "Time to Initial Use of Rescue Medication following the first application of ELS-M11", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Use of Rescue Medication within 24 hours following ELS-M11 application in patients experiencing moderate to severe migraine headaches.", 
                "measure": "Use of Rescue Medication following the first application of ELS-M11 by 24 hours", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Free of migraine-associated symptoms within 24 hours after ELS-M11 application in patients experiencing moderate to severe migraine headaches.", 
                "measure": "Resolution of migraine-associated symptoms, following the first application of ELS-M11", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Resuming or maintaining normal routine within 24 hours after first study medication application in moderate and severe headaches.", 
                "measure": "Percentage of patients who can resume or maintain their normal routine, following the first application of ELS-M11.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Achelios Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achelios Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}